On May 28, the website of the Chinese Center for Disease Control and Prevention published the "General Information on Adverse Reaction Monitoring of COVID-19 Vaccine Vaccination" jointly published by the center and the National Adverse Drug Reaction Monitoring Center.
Monitoring information shows that from December 15, 2020 to April 30, 2021, 31 provinces, municipalities, autonomous regions, and Xinjiang Production and Construction Corps reported 265 million doses of COVID-19 virus vaccine, and 31,434 cases of adverse reactions to vaccination were reported. The rate is 11.86/100,000 doses. Among the adverse reactions, 26,078 were general reactions, accounting for 82.96% of the total number of adverse reactions, and the reported incidence was 9.84 per 100,000 doses, including 2722 cases of high fever (≥38.6℃), 675 cases of redness (diameter ≥2.6 cm), and induration (Diameter ≥ 2.6 cm) 304 cases. There were 5356 cases of abnormal reactions, accounting for 17.04% of the total number of adverse reactions, and the reported incidence was 2.02 per 100,000 doses; the top 3 reactions reported were 3920 cases of allergic rash, 107 cases of angioedema, and 75 cases of acute severe allergic reactions. Among the abnormal reactions, there were 188 severe cases, and the reported incidence was 0.07/100,000 doses.
As of April 30, 2021, my country has reported 265 million doses of COVID-19 vaccine. The reported incidence of adverse reactions was 11.86 per 100,000 doses. Among them, the general reaction accounted for 83%, the reported incidence rate was 9.84 per 100,000 doses; the abnormal reaction accounted for 17%, the reported incidence rate was 2.02 per 100,000 doses, and the severe abnormal reaction rate was 0.07 per 100,000 doses. The probability is extremely rare (less than one in ten thousand). The general response and abnormal response rate of China's COVID-19 vaccine are lower than the average reported levels of other types of vaccines in 2019.
Copyright © 2024 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )
We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News.
sign-up for our newsletter today.
To ensure our newsletter hit your inbox, make sure to add @caclp.com to your safe senders list. And, as always, feel free to contact
us with any questions and thanks again for subscribing.